natgillin/translations-raw huggingface dataset:
Primycin or a primycin component represented by the following general formula (I) wherein R1 is n-butyl, n-pentyl or n-hexyl and R2 is arabinosyl, H or OH, which primycin component is in basic form or in salt form, or a combination of said primycin components for use in the treatment or prevention of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative Staphylococcus sp. 
Primicin ili komponenta primicina predstavljeni sljedećom općenitom formulom (I) gdje RI je n-butil, n-pentil ili n-heksil i R2 je arabinozil, H ili OH, koja komponenta primicina je u bazičnom obliku ili obliku soli, ili kombinacija te komponente primicina za uporabu u liječenju ili prevenciji infekcija uzrokovanih meticilin- rezistentnim Staphilococcus aureus (MRSA), meticilin-rezistentnim koagulaza-negativnim Staphilococcus sp.
The invention, and embodiments and further developments thereof, are explained in more detail in the description given below of examples of embodiments with reference to the drawings. BRIEF DESCRIPTION OF THE DRAWINGS 
Izum, izvedbe i njegov daljnji razvoj objašnjavaju se s više pojedinosti u dolje datom opisu primjera njegovih izvedbi pomoću crteža od kojih: slika 1
deprotecting the compound of Formula LX to give a compound of Formula LXI; 
Formula LX skidanje zaštite sa spoja Formule LX, čime se dobiva spoj formule LXI:
Less than 25% of the compound of Example 1 degraded to gemcitabine at pH range 1 to 8 after four hours. Pharmacokinetic Assays Mouse Pharmacokinetics 
Manje od 25 % spoja iz Primjera 1 razgradilo se u gemcitabin uz raspon pH od 1 do 8 nakon četiri sata, Farmakokinetička ispitivanja
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000. The solid oral extended release pharmaceutical dosage form of claim 78, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide. 
(1) najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; i (2) 60 mg ili 80 mg oksikodon hidroklorida; 1 pri čemu pripravak sadrži barem oko 60 % (težinski) polietilen oksida.
is any one protecting group selected from the group consisting of carbobenzyloxy, para-methoxybenzyl carbonyl, tert-butyloxycarbonyl, 9-fluorenyl methyloxy carbonyl, acetyl, benzoyl, benzyl and para-methoxybenzyl, 
je bilo koja zaštitna grupa izabrana iz grupe koja se sastoji od karbobenziloksi, para-metoksibenzil karbonil, terc-butiloksikarbonil, 9-fluorenil metiloksi karbonil, acetil, benzoil, benzil i para-metoksibenzil,
A heating device for a container of a liquid pharmaceutical product having a viscosity of 50-500 cP at 4°C and contained within a glass container, comprising a substantially rigid, thin-walled housing defining an openable chamber for receiving the container, a heat source in the chamber comprising a hermetically sealed package containing a super-cooled metal salt fluid or liquid and an actuator for activating the super-cooled metal salt to produce heat, wherein the ratio of the volume of the metal salt to the intended volume of the product is no more than 1:1. 
Grijač za spremnik tekućeg farmaceutskog proizvoda, viskoziteta od 50-500 cP pri 4"C, koji se nalazi unutar staklenog spremnika, obuhvaća čvrsto kučište tankih stijenki koje definira komoru koja se može otvoriti da bi se umetnuo spremnik, izvor topline u komori koji se sastoji od hermetički zatvorenog paketa koji sadrži super-ohlađeni fluid ili tekućinu metalne soli i aktivator koji potiče super-ohlađenu metalnu sol da proizvodi toplinu, gdje omjer volumena metalne soli prema željenom volumenu proizvoda nije veći od 1:1.
The cellulose reactive glyoxalated copolymer composition according to claim 1, wherein the ratio of the weight average molecular weight of the cationic copolymer before glyoxalation to weight % of diallyldimethylammonium halide monomer making up the cationic copolymer before glyoxalation is from 4,000 to 40,000 Daltons/weight %. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema bilo kojem od zahtjeva 1-6, gdje je omjer masenog prosjeka molekulske mase kationskog kopolimera prije glioksalacije u odnosu na maseni % dialildimetilamonij halid monomera koji čini kationski kopolimer prije glioksalacije 4000 do 40,000 Daltona/ masenom %.
separating precipitated calcium phosphate from said second leach solution; and 
razdvajanje (308) istaloženog kalcij fosfata iz spomenute druge otopine za ispiranje; te
The composition according to claim 1, wherein the anti-agglomerant is selected from the group consisting of talc, colloidal silicon dioxide, magnesium stearate, stearic acid and sodium fumaryl stearate. 
Pripravak u skladu patentnim zahtjevom 1 ili 2, naznačen time, da se sredstvo protiv aglomeriranja bira između talka, koloidnog silicijevog dioksida, magnezijevog stearata, stearinske kiseline i / ili natrijevog fumaril stearata.
A pharmaceutical formulation comprising an anti-IL-17 antibody at a concentration in the range of about 80 mg/mL to about 150 mg/mL, citrate buffer at a concentration of about 20 mM, sodium chloride at a concentration of about 200 mM, polysorbate-80 at a concentration in the range of about 0.02% (w/v) to about 0.03% (w/v), and pH at about 5.7, wherein the anti-IL-17 antibody comprises an antibody with an LCVR and an HCVR, wherein said LCVR is the amino acid sequence of SEQ ID NO: 2 and said HCVR is the amino acid sequence of SEQ ID NO: 3. 
Farmaceutska formulacija, naznačena time što sadrži protutijelo protiv IL-17 u rasponu koncentracija od 80 mg/ml do 150 mg/ml, citratni pufer u koncentraciji od 20 mM, natrijev klorid u koncentraciji od 200 mM, polisorbat-80 u rasponu koncentracija od 0,02% (tež./vol.) do 0,03% (tež./vol.), te pH od 5,7, gdje protutijelo protiv IL-17 sadrži protutijelo s lakim lancem (LC) i teškim lancem (HC), gdje navedeni LC ima aminokiselinski slijed sa SEQ ID NO: 4, a navedeni HC ima aminokiselinski slijed sa SEQ ID NO: 5.
Since no current is flowing in the hair-dryer 16 and, therefore, in the primary winding of transformer 30, in its secondary no current flows and, as a consequence, there is no voltage across resistor 85. 
S obzirom da ne teče struja u sušilu 16, a tako ni u transformatoru 30, nema struje ni u njegovom sekundaru, i kao posljedica, nema napona na otporniku 85.
a first separation step S4 which consists in the separation of the said mixture of products in a main column C4 into fraction A at the top of column C4 and into a fraction F4 at the bottom of column C4, and 
- prvi korak odvajanja S4 koji se sastoji u odvajanju navedene mješavine produkata unutar glavne kolone C4 u frakciju A na vrhu kolone C4 1 u frakciju F4 na dnu kolone C4, to
The composition of aspect 1, wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8 °C, for a period of 6 months, the composition will retain at least 85% of the stability the composition had prior to storage. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da poslije čuvanja u kontejneru nepropusnom za plin, na temperaturi od 2-8%C, u razdoblju od 6 mjeseci, kompozicija zadrži najmanje 85% stabilnosti koju je kompozicija imala prije čuvanja.
Figure 1 shows an X-ray diffraction pattern of the tablets comprising donepezil hydrochloride hydrate described in Example 4. 
Na Slici 1 prikazan je spektar difrakcije X-zraka na tabletama koje sadrže donepezil hidroklorid hidrat opisan u Primjeru
The process of item 27, wherein in step b) the composition is shaped to form an extended release matrix formulation in the form of tablet. 
Postupak prema zahtjevu 27, naznačen time da se u koraku b) sastav oblikuje tako da tvori formulaciju matrice s produljenim otpuštanjem u obliku tablete.
Excipient or Active Ingredient 
Inertni punitelj ili aktivno sredstvo
the mediator, present in the reagent composition at a concentration of at most 40 nmol per uL of the reservoir volume, 
HR P20151237 T1 posrednik u koncentraciji od najviše 40 nmol po uL volumena spremnika.
re-implantation of digits and limbs, strangulated bowel. Alternatively, in another preferred embodiment, the method is applied to prevent, reduce or treat a foreseen occurrence of ischemic reperfusion. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačena time što farmaceutski pripravak je namijenjen sprječavanju, smanjivanju ili liječenju očekivane pojave ishemije i reperfuzijske ozljedo.
The ring 1103 may be fixed to the container 1100 via threads or other coupling means known or developed in the art. 
Obruč 1103 može biti fiksiran za posudu 1100 preko navoja ili na drugi način poznat ili izveden u tehnici.
a plurality of active agent particles comprising crystalline glycopyrrolate, including any pharmaceutically acceptable salts, esters, or solvates thereof, wherein at least 90% of the active agent particle material by volume exhibits an optical diameter of 7 µm or less, said active agent particles are included in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of between 15 µg and 80 µg per actuation of the metered dose inhaler; and 
prva vrsta čestica aktivnog sredstva sadrži glikopirolat, uključujući bilo koje farmaceutski prihvatljive soli, estere, enantiomere, te smjese njihovih enantiomera ili solvata, gdje najmanje 90% prve vrste čestica aktivnog sredstva po volumenu pokazuje optički promjer od 7 µm ili manji, suspendirane u suspenzijskom mediju u koncentraciji dovoljnoj da osigura unesenu dozu glikopirolata od do 80 µg po aktuaciji inhalatora za odmjerene doze;
The pharmaceutically acceptable composition of claim 1, further comprising an agent that inhibits the formation of oxidation products. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 3, nadalje sadržeći agent koji inhibira stvaranje produkata oksidacije.
After drying at reduced pressure, this results in 0.68 g of a white solid corresponding to the product of interest. 
Nakon sušenja pod smanjenim tlakom dobije se 0,68 g bijele krute tvari koja odgovara željenom proizvodu.
Independently, where present, Z2 may be or comprise one or more amino acid residues. For example, Z2 may be a Y-Glu, Glu, B-Ala or e-Lys residue, or a 4-aminobutanoyl, 8-aminooctanoyl or 8-amino-3,6-dioxaoctanoyl moiety. 
(b) Z/ jest ili sadrži jedan ili više aminokiselinskih ostataka, primjerice gdje je Z* sljedeći ostatak: y-Glu, Glu, f- Ala ili g-Lys ili dio sljedeće skupine: 3-aminopropanoil, 4-aminobutanoil, 8-aminooktanoil ili 8-amino-3,6-dioksaoktanoil; i/ili
A is the A-chain of insulin lispro and has the amino acid sequence of SEQ ID NO: 1; B is the B-chain of insulin lispro and has the amino acid sequence of SEQ ID NO: 3; and P is a PEG having a molecular weight in the range from about 17.5 kDa to about 40 kDa, and wherein A and B are properly cross-linked and P is attached via a urethane covalent bond to the epsilon-amino group of the lysine at position 28 of B. 
P je PEG, čija je molekulska težina u rasponu od otprilike 17,5 kDa do otprilike 40 kDa; A je A-lanac inzulina lispro (SEQ ID NO: 1); B je B-lanac inzulina lispro (SEQ ID NO: 3); i gdje A i B su ispravno ukriženo povezani, a P je vezan preko uretanske kovalentne veze na g-amino skupinu lizina na položaju 28 u B; jednu ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili podloga; i terapijski djelotvornu količinu inzulina lispro.
-where the meanings of Ar1, R1, R4, R5, R6a, R6b, Y, Z, Ar2 are as defined in Claim 1.- is reacted with O -tosylhydroxylamine, or e.) to prepare the compounds of general formula (IA) and their salts -where Q represents -N--CO-R10 group -where R10 represents hydrogen atom, straight or branched C1-4 alkyl group, C3-6 cycloalkyl group, phenyl or benzyl group- and the meanings of Ar1, R1, R4, R5, R6a, R6b, Y, Z and Ar2 are as defined in Claim 1.- a compound of the general formula (IA) prepared by method d.) 
kako bi se dobilo spojeve opće formule (IA) i njihove soli, gdje Q predstavlja -N–-H skupinu, a značenja Ar1, R1, R4, R5, R6a, R6b, Y, Z i Ar2 su definirana kao u patentnom zahtjevu 1, spoj opće formule (I) dobiven postupkom a) ili b), gdje su značenja Ar1, R1, R4, R5, R6a, R6b, Y, Z i Ar2 definirana kao u patentnom zahtjevu 1, reagira s O-tosilhidroksilaminom; ili
Generation of monoclonal antibodies of the invention 
Datum objave europskog patenta:
The polymeric device material of claim 1 wherein the amount of monomer [1] is 80 to 95% (w/w). 
Polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 1, naznačen time što količina of monomer [1] je 80 to 95 % (težinski).
is hydrogen or a radical of formula wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and R11 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R11 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; 
(R"'), s £f (Qizh pri čemu s je cijeli broj jednak nuli, 1, 2, 3 ili 4; rje cijeli broj jednak 1, 2,3, 4ili5;i R"! je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R' radikala mogu se zajedno uzeti da sa fenilnim prstenom na kojeg su vezani tvore naftil;
a gear mechanism enabling the blister package to index and the medicament in dry powder form to become ready for inhalation; 
- mehanizam zupčanika koji omogućava da se indeksira blister pakiranje koje je u uporabi i da lijek u suhom praškastom obliku postane spreman za inhaliranje;
The first release device 118 can be configured to control or meter the amount or rate of first substance released from the first cartridge 114. In some embodiments, the inhalation device includes a single cartridge. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je uređaj za prvo oslobađanje (118) konfiguriran za isparavanje ili uplinjavanje prve tvari povezane s prvim spremnikom (114).
Trisaccharide derivate according to any of the claims 1-7, wherein the substituted trisaccharide core is derived from raffinose, melezitose or maltotriose and wherein the trisaccharide derivate is fully substituted with identical fatty acid ester groups per substituted trisaccharide. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačena time što se supstituiranu trisaharidnu jezgru izvodi iz rafinoze, melezitoze ili maltotrioze, te što je trisaharidni derivat posve supstituiran s istovjetnim esterskim skupinama masnih kiselina po supstituiranom trisaharidu.
The odour-absorbing composition according to claim 1, wherein the amount of said Y-cyclodextrins is equal to or higher than the total amount of said a-, and B-cyclodextrins. 
Sastav koji apsorbira neugodne mirise prema patentnom zahtjevu 1, naznačen time, da je količina navedenih Y-ciklodekstrina jednaka ukupnoj količini ili je veća od ukupne količine navedenih a- i B-ciklodekstrina.
an HVR-L2 comprising the amino acid sequence of SEQ ID NO:12; and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:13, and detecting the antibody bound to STEAP-1, or a naturally occurring allelic variant thereof, in said subject. 
(2) HVR-L2 koji sadrži aminokiselinsku sekvencu od SEQ ID NO: 12; 1 (3) HVR-L3 koji sadrži aminokiselinsku sekvencu od SEQ ID NO: 13; - < te otkrivanje, kod navedenog pojedinca, protutijela vezanog za STEAP-I, ili njegove alelne varijante koja se prirodno pojavljuje.
The reaction mixture was then acidified with 6N hydrochloric acid (200 ml. 
Reakcijska smjesa se tada zakiseli sa 6N klorovodičnom kiselinom (200 ml.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A compound according to claim 43 wherein R15 is hydrogen or C1-C3 alkyl and Y is a covalent bond. 
Spoj u skladu s patentnim zahtjevom 43, naznačen time što R15 je vodik ili C1-C3 alkil, a Y je kovalentna veza.
The expanded polystyrene particle according to claim 1, wherein the methylene diphenyl diisocyanate is present in an amount of 0.1 to 30% by weight, based on the weight of the expanded polystyrene particle. 
Čestica ekspandiranog polistirena u skladu s patentnim zahtjevom 1, naznačena time što metilen-difenil-diizocijanat je prisutan u količini od 0,1 do 30%, težinski, na osnovi težine čestice ekspandiranog polistirena.
The method of Claim 20, wherein said fermentation medium is a food product such as a dairy product, for example milk 
Postupak prema zahtjevu 20, naznačen time da navedeni fermentacijski medij je prehrambeni proizvod kao što je mliječni proizvod, na primjer mlijeko
combining the mutant leukocidin subunit or polypeptide complex with an adjuvant. 
(b) kombiniranje mutantne podjedinice leukocidina ili polipeptidnog kompleksa s pomoćnim sredstvom.
V is selected from the group consisting of O, S, NH, and NHRb; 
se bira iz skupine koju čine vodik i C1-4 alkil;
The method of any of the preceding claims, wherein the subject to be treated has a HbA1 c value in the range of 7 % to 10% or/and a fasting plasma glucose concentration of at least 7 mmol/L or/and 2 hours postprandial plasma glucose of at least 11.1 mmol/L. A pharmaceutical combination comprising 
Kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što subjekt kojeg treba liječiti vrijednost ima HbAlc u rasponu od 7% do 10% ili/i koncentraciju glukoze u plazmi tijekom gladovanja od najmanje 7 mmol/l ili/i koncentraciju glukoze u plazmi 2 sata nakon obroka od najmanje 11,1 mmol/I.
at least one resin. 
- najmanje jednu smolu.
A composition according to claim 1, wherein component (B1) is a fungicide selected from the group consisting of azoxystrobin, fluoxastrobin, picoxystrobin, pyraclostrobin, and trifloxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (B) fungicid odabran od azoksistrobina, fluoksastrobina, pikoksistrobina, piraklostrobina i trifloksistrobina.
o a first hook-and-loop connecting element fixed to said second zone thereby providing a hook-and-loop surfaced area. 
o prvi kuka-i-petlja spojni element učvršćen na navedenu drugu zonu te se tako osigurava kuka-i-petlja oplošje.
While many methods are now available for large-scale preparation of proteins, crude products, such as body fluids, contain not only the desired product but also impurities which are difficult to separate from the desired product. 
Dok većina postupaka nije prikladna za pripremu velikih količina proteina, grubi produkti poput tjelesne tekućine sadrže ne samo željene produkte već i kontaminacije koje se teško odvajaju iz željenog produkta.
A motor (1) as claimed in claim 19, further comprising means for controlling the source of motive power (12) so as to cause the body (2) to rotate about the first axis (4) at said rotational speed in excess of the predetermined value. 
Motor (1) prema Zahtjevu 22, naznačen time, da su povratna sredstva (17, 18. 19, 20) uređena na takav način da prenesu dovoljnu količinu pogonske snage na izvor (12) pogonske snage tako da nadoknade gubitak energije koji je
“C3-7alkyl” means a straight chain or branched, noncyclic or cyclic hydrocarbon containing from 3 to 7 carbon atoms. 
"Cagalkil" znači nerazgranati ili razgranati, neciklički ili ciklički ugljikovodik s 3 do 7 atoma ugljika.
Reference 36 describes a study where SDS was added to IL-2 preparations containing, like the PROLEUKIN™ product, 1.1 mg of IL-2. 
Referenca 36 opisuje studiju gdje se SDS dodavalo preparatima IL-2, koji su kao proizvod PROLEUKINTM sadržavali 1,1 mg IL-2.
A process for producing knitted articles on at least a circular knitting machine (1) for knitwear or hosiery, comprising a process for regulating the size of knitted articles under production on circular knitting machines for knitwear or hosiery, the process for regulating the size of knitted articles comprising the steps of: 
Postupak reguliranja veličine pletenih artikala koji se proizvode na kružnim strojevima za pletenje pletenih odjevnih predmeta ili čarapa, koji sadrže sljedeće korake:
each A is independently selected from O, S and NR12; Y1, Y2 and Y4 are independently selected from the group consisting of carbon and nitrogen, 
Y', YZi Y" su neovisno izabrani iz skupine koju čine ugljik i dušik, pri čemu Y? je dušik i R* je odsutan; te ako Y' je dušik tada R* je odsutan;
About 40 to 60 weight % of the resistant maltodextrin is oligosaccharide resistant maltodextrin and has a DP below 10. 
Oko 40 do 60 težinskih % rezistentnog maltodekstrina je maltodekstrin rezistentan na oligosaharid i ima DP manji od 10.
Compound according to claim 1 (D-79), optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof 
Spoj prema zahtjevu 1, naznačen time, da je (D-79), [image], opcijski u obliku tautomera, racemata, enantiomera, dijastereomera, i njihovih mješavina, i opcijski u obliku njihovih farmakološki prihvatljivih soli.
Diseases or disorders associated with TTR misfolding include, but are not limited to, familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, Alzheimer's disease, spongiform encephalopathy (i.e., Creutzfeldt Jakob disease GSS, fatal familial insomnia), frontotemporal dementia, Parkinson's disease amyotrophic lateral sclerosis (ALS), Down Syndrome, multiple sclerosis, polyneuropathy, Guillain-Barre′ syndrome, macular degeneration, vitreous opacities, glaucoma, type II diabetes or medullary carcinoma of the thyroid. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili sastav prema zahtjevu 6, naznačen time, da se upotrebljava u liječenju porodične amiloidne polineuropatije, porodične amiloidne kardiomiopatije, senilne sustavne amiloidoze, Alzheimerove bolesti, Creutzfeldt Jakob-bolesti GSS, opasne porodične insomnije, frontotemporalne demencije, Parkinsonove bolesti, amiotrofne lateralne skleroze (ALS), Downovog sindroma, multiple skleroze, polineuropatije, Guillain-Barre-sindroma, makularne degeneracije, zamućenja staklovine, glaukoma, dijabetesa tipa IL, ili medularnog karcinoma tiroida.
In a further preferred embodiment, R14 represents an unsubstituted, a mono- or disubstituted phenyl group, substituted with methyl or halogen, and R15 represents lower alkyl. 
Derivati tiazolidin-4-ona prema zahtjevima 4 do 9, naznačeni time, da R"" predstavlja nesupstituiranu, ili a mono- ili di-supstituiranu fenilnu skupinu, supstituiranu metilom ili halogenom, a R"* predstavlja niži alkil.
Various devices for blending various liquids and solids have been developed over the years. 
Proteklih godina su osmišljeni razni uređaji za miješanje različitih tekućina i čvrstih tvari.
the electrodes are configured to align and connect to the electrodes of a vehicle cigarette lighter socket; the material infused with the fragrance is a solid in the shape of a flat ring; and 
se kod materijala (114) koji je natopljen aromom, radi o krutoj tvari u obliku plosnatog prstena; i kapica (116) obuhvaća ventil (110) koji je djelotvoran za raspršivanje arome.
Immunoglobulin single variable domain (ISVD) having the amino acid sequence according to SEQ ID NO: 40. 
Imunoglobulinska jednostruka varijabilna domena (ISVD) naznačena time da ima sekvencu amino kiseline u skladu sa SEQ ID NO: 40.
determining a remaining mode set comprising a plurality of remaining modes other than said three MPMs; 
određivanje skupa preostalih modova koji sadrži više preostalih modova koji nisu navedena tri MPM;